A key reason for buying this Canadian energy stock — our Top Pick for speculative investors — was the management, asserts Benj Gallander, contrarian advisor and editor of Contra the Heard.
This experienced team appeared to have what it takes to lead acquiring Penn West Petroleum (PWE) through a crisis. And the group has taken bold steps to deleverage the company, selling assets while cutting expenses and eliminating the dividend.
Tough decisions have been the order of the day. At the end of 2015, debt stood at $2.1 billion. It’s now down to $576 million, which lets the company to say “buh-bye” to the unsightly auditors’ “going concern” tag. All of the positives caught the eyes of a flurry of investors and the share price popped.
In November, PWT paid off another $448 million at par and on a pro rata basis. The cash was available thanks to the sale of assets in Saskatchewan, and management is prepared to use it in what we debt-averse guys believe is a positive manner. Wow! Talk about a revamped enterprise!
Top 5 Canadian Stocks To Own For 2019: Prestige Brand Holdings Inc.(PBH)
Advisors' Opinion:- [By Joseph Griffin]
Prestige Consumer Healthcare Inc (NYSE:PBH) – Stock analysts at William Blair cut their Q4 2019 earnings estimates for shares of Prestige Consumer Healthcare in a report released on Thursday, February 7th. William Blair analyst J. Andersen now forecasts that the company will post earnings of $0.69 per share for the quarter, down from their previous forecast of $0.70. William Blair also issued estimates for Prestige Consumer Healthcare’s FY2020 earnings at $2.80 EPS.
- [By Max Byerly]
Premium Brands Holdings Corp (TSE:PBH) has earned an average recommendation of “Buy” from the seven analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is C$132.14.
- [By Stephan Byrd]
SG Americas Securities LLC increased its position in Prestige Brands (NYSE:PBH) by 103.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,597 shares of the company’s stock after acquiring an additional 8,431 shares during the period. SG Americas Securities LLC’s holdings in Prestige Brands were worth $560,000 at the end of the most recent reporting period.
Top 5 Canadian Stocks To Own For 2019: Rhino Resource Partners LP(RNO)
Advisors' Opinion:- [By Ethan Ryder]
Renold (LON:RNO) announced its earnings results on Tuesday. The company reported GBX 4.50 ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of GBX 4.50 ($0.06), Bloomberg Earnings reports. Renold had a return on equity of 201.92% and a net margin of 4.30%.
- [By Ethan Ryder]
JPMorgan Chase & Co. set a €98.00 ($113.95) price target on Renault (EPA:RNO) in a research note released on Monday. The firm currently has a neutral rating on the stock.
- [By Shane Hupp]
Deutsche Bank set a €115.00 ($133.72) target price on Renault (EPA:RNO) in a report released on Friday morning. The firm currently has a buy rating on the stock.
- [By Logan Wallace]
JPMorgan Chase & Co. set a €74.00 ($86.05) target price on Renault (EPA:RNO) in a research report report published on Thursday morning. The firm currently has a neutral rating on the stock.
- [By Logan Wallace]
Credit Suisse Group set a €73.00 ($84.88) price objective on Renault (EPA:RNO) in a research report sent to investors on Tuesday morning. The brokerage currently has a neutral rating on the stock.
Top 5 Canadian Stocks To Own For 2019: Sensata Technologies Holding N.V.(ST)
Advisors' Opinion:- [By Logan Wallace]
Get a free copy of the Zacks research report on Sensata Technologies (ST)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Get a free copy of the Zacks research report on Sensata Technologies (ST)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Canaccord Genuity assumed coverage on shares of Sensata Technologies (NYSE:ST) in a note issued to investors on Friday, The Fly reports. The firm set a “buy” rating on the scientific and technical instruments company’s stock.
Top 5 Canadian Stocks To Own For 2019: Transcananda Pipelines Ltd.(TRP)
Advisors' Opinion:- [By Matthew DiLallo]
Meanwhile, TransCanada (NYSE:TRP) has been working to revive its Keystone XL pipeline. After years of delay, TransCanada could start full construction next year, which would put the line into service by 2021. However, the hotly contested pipeline could face new delays or even another rejection.
- [By Logan Wallace]
Enterprise Products Partners (NYSE: TRP) and TC PIPELINES LP Common Stock (NYSE:TRP) are both large-cap oils/energy companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.
- [By Jason Hall]
Priestley: Yeah, absolutely. The last company is also on this natural gas trend, it's TransCanada (NYSE:TRP), ticker TRP. It's a Canadian energy infrastructure company. They have assets in the U.S., Canada, obviously, and Mexico. They operate 40,000 miles of natural gas pipeline. A notable project that they operate is the Keystone XL Pipeline and the Keystone Pipeline system. It also has interests in 20 power generation facilities, mostly in Canada. And, they have significant scale as a midstream company. I kind of like these midstream players, because they're really winners, so to speak, in a lot of respects. A lot of the contracts that they make with the oil refiners or the oil companies themselves are 15-20-year contracts.
Top 5 Canadian Stocks To Own For 2019: Patni Computer Systems Limited(PTI)
Advisors' Opinion:- [By Chris Lange]
Proteostasis Therapeutics Inc. (NASDAQ: PTI) saw its shares slide early on Thursday after the company reported that it had positive data from its early stage trial in cystic fibrosis (CF). These results come from the firm's ongoing Phase 1 dosing study of PTI-801 in CF patients on background Orkambi (lumacaftor/ivacaftor) therapy.
No comments:
Post a Comment